Literature DB >> 25359333

A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.

Akos Somoskovi1, Vera Bruderer2, Rico Hömke3, Guido V Bloemberg2, Erik C Böttger3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25359333     DOI： 10.1183/09031936.00142914

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  31 in total

1.  First use of bedaquiline in a patient with XDR-TB in Singapore.

Authors:  Angeline Poh-Gek Chua; Grace Si-Ru Hoo; Cynthia Bin-Eng Chee; Yee Tang Wang
Journal:  BMJ Case Rep       Date:  2015-09-23

2.  Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.

Authors:  Shuo Zhang; Jiazhen Chen; Peng Cui; Wanliang Shi; Wenhong Zhang; Ying Zhang
Journal:  J Antimicrob Chemother       Date:  2015-06-04       Impact factor: 5.790

3.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

4.  Ionophoric effects of the antitubercular drug bedaquiline.

Authors:  Kiel Hards; Duncan G G McMillan; Lici A Schurig-Briccio; Robert B Gennis; Holger Lill; Dirk Bald; Gregory M Cook
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

5.  Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384.

Authors:  Iman Halloum; Albertus Viljoen; Varun Khanna; Derek Craig; Christiane Bouchier; Roland Brosch; Geoffrey Coxon; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Authors:  Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.

Authors:  Peter M Keller; Rico Hömke; Claudia Ritter; Giorgia Valsesia; Guido V Bloemberg; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

8.  Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.

Authors:  Matthias Richard; Ana Victoria Gutiérrez; Albertus Viljoen; Daniela Rodriguez-Rincon; Françoise Roquet-Baneres; Mickael Blaise; Isobel Everall; Julian Parkhill; R Andres Floto; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

9.  Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.

Authors:  Jian Xu; Bin Wang; Minghao Hu; Fengmin Huo; Shaochen Guo; Wei Jing; Eric Nuermberger; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

10.  Drug-resistance mechanisms and tuberculosis drugs.

Authors:  Claudio U Köser; Babak Javid; Kathleen Liddell; Matthew J Ellington; Silke Feuerriegel; Stefan Niemann; Nicholas M Brown; William J Burman; Ibrahim Abubakar; Nazir A Ismail; David Moore; Sharon J Peacock; M Estée Török
Journal:  Lancet       Date:  2015-01-24       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.